文献速递技术与安全胸部腹部US

超声分子成像可视化免疫生物标志物用于肿瘤免疫治疗反应评估

Ultrasound Molecular Imaging and Visualization of Immune Biomarkers: A New Paradigm for Tumor Immunotherapy Response Assessment.
PubMed 文献 · Ultrasound Med Biol · 2026-09-11

本文为综述,系统阐述超声分子成像(USMI)可视化肿瘤免疫生物标志物的最新进展。重点剖析声学成像机制、免疫靶向微泡/纳米泡探针设计,并汇总黑色素瘤、肝细胞癌、非小细胞肺癌、结直肠癌和乳腺癌的临床前研究。USMI可动态追踪免疫细胞浸润与免疫检查点表达,用于疗效早期预测及假性进展、超进展与真性进展的鉴别。

要点

  • USMI可用于动态追踪肿瘤免疫细胞浸润和免疫检查点表达的空间分布。
  • USMI有助于早期预测免疫治疗疗效,并鉴别假性进展、超进展与真性进展。
  • USMI具备无辐射、低成本、高时空分辨率和可重复全瘤可视化优势,可作为PET-CT和MRI的互补手段。

核心结论

  • USMI是一种新型的肿瘤免疫治疗功能评估范式,在免疫分子成像中具有不可替代的优势。
  • USMI信号与病理免疫组化、转录组谱及纵向免疫治疗结局具有相关性。
  • USMI与PET/MRI互补,可用于肿瘤免疫微环境动态监测。

研究设计与样本

  • 本文为综述,系统阐述USMI可视化肿瘤免疫生物标志物的最新进展。
  • 深入剖析核心声学成像机制,以及免疫靶向微泡/纳米泡探针的合理设计与多功能优化策略。
  • 全面整理黑色素瘤、肝细胞癌、非小细胞肺癌、结直肠癌和乳腺癌的里程碑式临床前研究。

关键影像表现/征象

  • USMI可动态追踪免疫细胞浸润及其空间分布。
  • USMI可定量绘制整体免疫检查点表达图谱。
  • USMI可用于早期预测治疗疗效,并鉴别假性进展、超进展与真性肿瘤进展。

诊断标准与关键数值

  • USMI信号与病理免疫组化、转录组谱及纵向免疫治疗结局进行关联验证。

临床应用与阅片要点

  • USMI可作为常规RECIST标准和组织活检的补充手段,用于动态反映肿瘤免疫微环境。
  • 临床转化应用中,USMI可用于免疫细胞浸润的动态追踪和免疫检查点表达的定量评估。
  • 需注意探针脱靶结合、标准化定量流程不足和深部组织超声衰减等转化瓶颈。

局限性

  • 存在探针脱靶结合问题。
  • 标准化定量流程不足。
  • 深部组织超声衰减限制应用。
  • 临床转化需标准化多中心验证框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Cancer immunotherapy has revolutionized the treatment landscape, yet its clinical efficacy is limited by modest objective response rates and the emergence of atypical response patterns such as pseudoprogression and hyperprogression. Conventional RECIST criteria relying on anatomical size changes and invasive tissue biopsies suffer from prominent sampling bias and cannot dynamically reflect the heterogeneous tumor immune microenvironment (TIME), creating an urgent demand for non-invasive, real-time functional imaging tools to longitudinally profile intra-tumoral immune landscapes. Ultrasound molecular imaging (USMI) stands out as a distinctive imaging modality complementary to PET-CT and MRI, featuring radiation-free operation, low cost, superior spatiotemporal resolution and repeatable whole-tumor visualization-advantages that overcome the limitations of ionizing radiation, high expense and static single-spot sampling inherent to mainstream molecular imaging modalities. This review systematically elaborates state-of-the-art advances in USMI for visualizing tumor immune biomarkers, with in-depth dissection of core acoustic imaging mechanisms, rational design and multi-functional optimization strategies of immune-targeted microbubble/nanobubble probes and comprehensive collation of landmark pre-clinical investigations across melanoma, hepatocellular carcinoma, non-small cell lung cancer, colorectal and breast cancers. We thoroughly correlate USMI signal readouts with pathological immunohistochemistry, transcriptomic profiles and longitudinal immunotherapy outcomes, and elaborate on its core translational applications: dynamic tracking of immune cell infiltration and spatial distribution, quantitative mapping of global immune checkpoint expression, early prediction of therapeutic efficacy and differential diagnosis of pseudoprogression, hyperprogression and true tumor progression. We further highlight the inherent uniqueness of USMI for TIME surveillance and its complementary value relative to PET/MRI and objectively dissect critical translational bottlenecks, including probe off-target binding, insufficient standardized quantitative pipelines and deep-tissue ultrasound attenuation. Rather than overstating preliminary exploratory work, we rationally discuss the synergistic integration of USMI with multi-omics and artificial intelligence radiomics as a forward-looking developmental direction and propose theranostic probe engineering and standardized multi-center validation frameworks to accelerate clinical translation. This review constructs a complete theoretical and technical framework positioning USMI as a novel functional assessment paradigm for tumor immunotherapy, clarifies its irreplaceable strengths in immune molecular imaging and provides targeted insights to advance precision tumor immunotherapy evaluation.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Zhang, Xiao, He, et al. Ultrasound Molecular Imaging and Visualization of Immune Biomarkers: A New Paradigm for Tumor Immunotherapy Response Assessment. Ultrasound Med Biol. 2026. PMID: 42722534. doi:10.1016/j.ultrasmedbio.2026.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。